Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment.

Background and Objectives: Brolucizumab (IVBr) is a recently introduced anti-vascular endothelial growth factor (anti-VEGF) which has been found to be very effective in treating neovascular age-related macular degeneration (nAMD). We reported our findings in a case of nAMD that developed intraocular inflammation (IOI) after IVBr injections. Materials and Methods: A 79-year-old man was referred to our hospital complaining of reduced vision in both eyes of one-month's duration. His decimal best-corrected visual acuity (BCVA) was 0.9 in the right eye and 1.0 in the left eye. He was diagnosed with nAMD in the left eye and was treated with intravitreal aflibercept (IVA). Despite the three-monthly IVA injections, the serous retinal pigment epithelial detachment (PED) and subretinal fluid (SRF) remained, and the VA gradually decreased to 0.1. Because of the patient being refractory to aflibercept treatment, we switched to 3-monthly IVBr injections. The BCVA gradually improved to 0.3 and optical coherence tomography (OCT) showed an absence of the serous PED and SRF. Three weeks after his third IVBr, he returned to our hospital with a complaint of reduced vision in his left eye that he first noted two weeks earlier. Our examination of the left eye showed signs of IOI mainly in the anterior chamber. The inflammation improved with topical steroids but the treatment of the IOI was delayed for two weeks. The patient was instructed that it was important to begin the treatment as soon as the symptoms of IOI developed. We then performed the Mini-Mental State Examination (MMSE), and his score indicated that he had cognitive impairment. Conclusions: We concluded that before beginning IVBr treatment in nAMD patients, a careful assessment must be made of the cognitive status of the patient.

Case of unilateral pellucid marginal corneal degeneration progressing to corneal perforation with keratoconus in contralateral eye.

PURPOSE: To report our findings in a case of pellucid marginal corneal degeneration (PMCD) in the left eye and keratoconus (KC) in the right eye, and to review earlier cases of PMCD and KC. OBSERVATIONS: A 45-year-old woman visited our hospital with a complaint of reduced vision in her right eye. She was predisposed to allergies since childhood and had a habit of rubbing her eyes. Based on the results of the corneal topographic study, we diagnosed her with KC in the right eye and PMCD in the left eye. We prescribed a rigid, gas permeable contact lens and treated her allergic conjunctivitis with ocular medications. Three years after her initial visit, she developed a corneal perforation in the left eye. The perforation was closed by conservative treatment consisting of therapeutic soft contact lens wear. One year after the cornea healed, the corneal astigmatism in the left eye was about one-half of what it was before the corneal perforation. Her corrected visual acuity improved to 1.0 with conventional spectacles. CONCLUSIONAND IMPORTANCE: We found a difference in the progression of KC and PMCD even when they occurred in same individual. We suggest that the atopic predisposition, which is considered a risk factor for acute hydrops in KC, to be a risk factor for acute hydrops and corneal perforation in eyes with PMCD.